Journal of Applied Physiology, Vol 67, Issue 5 1770-1775, Copyright © 1989 by American Physiological Society

ARTICLES

Tissue glucose utilization during epinephrine-induced hyperglycemia

K. Meszaros, C. H. Lang, D. M. Hargrove and J. J. Spitzer
Department of Physiology, Louisiana State University Medical Center, New Orleans 70112.

The aim of this study was to investigate glucose utilization by individual tissues during epinephrine infusion. First, the applicability of the 2-deoxyglucose (2-DG) tracer technique during in vivo hyperglycemia was investigated in model systems in vitro. Epitrochlearis muscle and spleen cells were incubated with 1.25-20 mM glucose. The discrimination against 2-[14C]DG in glucose metabolic pathways, expressed by the lumped constant, remained unchanged over this wide range of glucose concentrations. It was concluded that in vivo hyperglycemia does not preclude the application of the 2-DG method. In a series of in vivo experiments, chronically catheterized conscious rats fasted for 24 h and were infused with epinephrine (0.2 microgram.kg-1.min-1), which produced a two-fold increase in plasma glucose concentration. 2-[14C]DG was injected 30 min after starting the epinephrine infusion and glucose utilization rates of individual tissues were calculated based on the concentration of phosphorylated 2-DG in samples excised at 70 min. The epinephrine infusion increased glucose utilization rates by 40-160% in hindlimb muscles, skin, ileum, liver, spleen, lung, epididymal fat, and kidney, although no change was found in the brain. Mass action of the increased plasma glucose is likely to play an important role in the enhanced rate of glucose utilization.

This article has been cited by other articles:

				J. Shearer, P. T. Fueger, J. N. Rottman, D. P. Bracy, P. H. Martin, and D. H. Wasserman AMPK stimulation increases LCFA but not glucose clearance in cardiac muscle in vivo Am J Physiol Endocrinol Metab, November 1, 2004; 287(5): E871 - E877. [Abstract] [Full Text] [PDF]

				J. Shearer, P. T. Fueger, B. Vorndick, D. P. Bracy, J. N. Rottman, J. A. Clanton, and D. H. Wasserman AMP Kinase-Induced Skeletal Muscle Glucose But Not Long-Chain Fatty Acid Uptake Is Dependent on Nitric Oxide Diabetes, June 1, 2004; 53(6): 1429 - 1435. [Abstract] [Full Text] [PDF]

				D. G. Hunt, Z. Ding, and J. L. Ivy Clenbuterol prevents epinephrine from antagonizing insulin-stimulated muscle glucose uptake J Appl Physiol, March 1, 2002; 92(3): 1285 - 1292. [Abstract] [Full Text] [PDF]

				A. E. Halseth, D. P. Bracy, and D. H. Wasserman Functional limitations to glucose uptake in muscles comprised of different fiber types Am J Physiol Endocrinol Metab, June 1, 2001; 280(6): E994 - E999. [Abstract] [Full Text] [PDF]

				A. E. Halseth, D. P. Bracy, and D. H. Wasserman Limitations to exercise- and maximal insulin-stimulated muscle glucose uptake J Appl Physiol, December 1, 1998; 85(6): 2305 - 2313. [Abstract] [Full Text] [PDF]

				A. L. Castle, C.-H. Kuo, and J. L. Ivy Amylin influences insulin-stimulated glucose metabolism by two independent mechanisms Am J Physiol Endocrinol Metab, January 1, 1998; 274(1): E6 - E12. [Abstract] [Full Text] [PDF]